UPDATE: Goldman Sachs Downgrades Amarin Corporation (AMRN) to Sell
- S&P ends modestly lower as rising Treasury yields offset robust retail data
- Electronic Arts (EA) Rebounds on Reaffirmed Guidance Despite Battlefield 2042 Delay, Be Concerned But Not Worried Says Analyst
- U.S. retail sales surprise to upside in strong boost to economy
- Chat Platform Discord Raises $500 Million, Valuation More Than Doubled In Less Than a Year
- Dollar index climbs after U.S. retail sales show surprise rebound
Goldman Sachs analyst Paul Choi downgraded Amarin Corporation (NASDAQ: AMRN) from Neutral to Sell with a price target of $5.00 (from $6.00).
THe analyst comments "Our view is supported by conversations with physicians who overwhelmingly indicate plans to prescribe generic products, particularly given coverage and cost challenges associated with branded Vascepa. While we remain positive on the opportunity for Vazkepa in Europe and other regions (e.g., China), it takes ~12 months for new products to achieve reimbursement in most major European countries (excluding Germany); as Vazkepa was just approved by the EMA in March and AMRN does not plan to launch the product until 3Q21, we do not expect meaningful growth
in Europe until 2022 and beyond. Against this backdrop, we see increasing urgency for AMRN to engage in more active business development to develop the pipeline that can be commercial-ready ahead of European loss of exclusivity in the early 2030s."
Shares of Amarin Corporation closed at $4.61 yesterday.
You May Also Be Interested In
- UPDATE: Piper Sandler Downgrades Beyond Meat Inc. (BYND) to Underweight, IRI Points to a Miss
- Avis Budget (CAR) Gains on BofA Upgrade to Buy on Expected Upward Revisions to 2022+ Estimates
- Beyond Meat (BYND) Slips on Downgrade to Underweight at Piper Sandler as 2H Expectations Are Likely Too High
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Comments, Hot Downgrades
Related EntitiesGoldman Sachs
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!